

Modern biomarkers in IgA vasculitis with nephritis in children

KAROLINA CICHON-KAWA¹, EMILIA PŁATOS^{1,2}, WOJCIECH WASIAK², MAŁGORZATA MIZERSKA-WASIAK¹

¹Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland

²Student's Scientific Group of the Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland

Abstract

Immunoglobulin A (IgA) vasculitis (IgAV) is the most common form of vasculitis in the pediatric population. From 30% to 60% of children with IgAV are affected by the accumulation of deposits of IgA in the glomeruli and the development of nephropathy in the course of IgA vasculitis with nephritis (IgAVN).

Besides well-known factors such as proteinuria or lower glomerular filtration rate (GFR), the need for the identification of early disease biomarkers was also pointed out. These biomarkers would enable us to predict the disease course in a non-invasive way and focus the therapy on risk stratification. We are searching for markers that will allow us to predict the progress of nephropathy in the course of IgAV or the severity of IgAVN.

The aim of the study is to present the currently known biomarkers in IgAVN. We present the significance of GDIGAI, anti-GDIGAI, the immune complexes Gd-IgA1-anti-Gd-IgA1, FcαRI/CD89, sTfR/CD71, interleukin (IL)-6 and IL-8, KIM-1, MCP1, NAG, UAGT and vanin-1 and metabolomic factors in IgAVN in children.

Key words: children, biomarkers, IgA vasculitis nephritis.

(*Cent Eur J Immunol* 2025; 50 (4): 389-396)

Introduction

Immunoglobulin A (IgA) vasculitis (IgAV) is the most common form of vasculitis in the pediatric population. According to global registers, it is estimated that the prevalence among children ranges between 3 and 26,7 cases per 100,000 people [1-3]. Based on the 2008 IgAV classification criteria adopted by EULAR (the European League Against Rheumatism), PRINTO (the Paediatric Rheumatology International Trials Organisation) and PRES (the Paediatric Rheumatology European Society), a mandatory/obligatory criterion to diagnose IgAV is palpable purpura with at least one of the following symptoms: abdominal pain, typical histopathological changes, arthritis or arthralgia, renal involvement (hematuria and/or proteinuria) and IgA deposition in biopsy specimens (Table 1) [4-6]. From 30% to 60% of children with IgAV are affected by the accumulation of deposits (e.g. IgA) in glomeruli and the development of nephropathy in the course of IgA vasculitis with nephritis (IgAVN) [7]. In most cases, the disease is self-limiting, although 2-20% of the patients develop end-stage renal disease [2, 8]. The mild clinical course applies to patients with erythrocyturia and/or mild proteinuria (< 1 g/day, and UP : UC ratio < 100 mg/mmol); however,

in around 20% of the patients with renal involvement, the disease manifests as nephrotic or nephritic syndrome [9, 10]. It may also present as impaired renal function, which increases the risk of progression to end-stage renal disease, which was detected in 1-7% of the cases [11-13].

Old age and low glomerular filtration rate (GFR) are well-known risk factors for the unfavorable course of IgAVN [12, 14]; however, researchers have not reached a consensus on these conclusions and in publications of Kawasaki *et al.* and Mir *et al.* did not observe this correlation [15, 16]. According to the latest meta-analysis gender is not significantly associated with poor outcomes in IgAVN [12], whereas a higher risk of developing IgAVN among patients with IgAV is found in boys [17]. In terms of urine changes, presence of nephrotic and nephritic-nephrotic syndrome is associated with a worse prognosis, whereas hematuria and mild proteinuria with/without hematuria have good clinical outcomes. Nephrotic syndrome persisting over three months was particularly related to poor prognosis. Also, the nephritic-nephrotic syndrome is an independent factor associated with unfavorable outcomes, whereas acute nephritic syndrome does not show this correlation [12].

Correspondence: Małgorzata Mizerska-Wasiak, MD, PhD, Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland, e-mail: mmizerska@wum.edu.pl
Submitted: 19.01.2024, Accepted: 24.05.2024

Table 1. Classification criteria for immunoglobulin A (IgA) vasculitis (their fulfilment classifies this form of vasculitis with a sensitivity of 100% and a specificity of 87% [5])

Criterion	Discussion	Sensitivity	Specificity
1 Purpura (obligatory/mandatory criterion)	Purpura (usually palpable and clustered) or petechiae, mainly in the lower limbs, unrelated to thrombocytopenia	89%	86%
and ≥ of the following criteria are met			
2 Abdominal pain	Diffuse colicky abdominal pain based on interview and physical examination. May include intussusception or gastrointestinal bleeding	61%	64%
3 Histopathological examination	Typically leukocytoclastic vasculitis with predominantly IgA deposits or proliferative glomerulonephritis with predominantly IgA deposits	93%	89%
4 Arthritis or arthralgia	Arthritis of acute onset defined as swollen or painful joints with restricted Arthralgia of acute onset defined as joint pain without swelling or restriction of mobility	78%	42%
5 Renal involvement	Proteinuria > 0.3 g/day or albumin/creatinine ratio in morning urine sample > 30 mmol/mg Hematuria or presence of erythrocyte rollers: > 5 erythrocytes or erythrocyte rollers in the field of view in a urine sediment examination or a test result in a strip test	33%	70%

As before, the gold standard of diagnosis and severity assessment of IgAVN is a kidney biopsy [10, 16]. For the evaluation of histopathological findings in the kidney, the Oxford classification, which so far has not been validated for IgAVN but has for IgA nephropathy (IgAN), is increasingly used [13, 18]. This scoring system includes five histologic parameters which form the MEST-C score: M – mesangial hypercellularity score (M0 ≤ 50% glomeruli, M1 > 50% glomeruli); E – the presence of endocapillary proliferation (E = 0: absent, E = 1: present), S – segmental glomerulosclerosis/adhesion (S0: absent, S1: present), T – the severity of tubular atrophy/interstitial fibrosis (T0 ≤ 25%, T1: 26-50%, T2 > 50%), C – crescents (C0 – absent, C1 < 25% of glomeruli, C2 > 25% of glomeruli) [19]. It is considered that this scale can be used to predict progression of nephropathy in the course of IgAVN as well as correlating with extra-renal symptoms – associated abdominal symptoms predispose to higher MEST-C scores [13]. The presence of crescents in the biopsy samples has an unfavorable prognosis [6, 10, 12, 13, 20].

Since renal biopsy is an invasive procedure, there is a need for less invasive diagnostic procedures. Measurement of biomarkers in urine and in blood seems to be promising method. However, none of them has yet proved to be an established marker of disease and further studies are needed.

In the vast majority of patients with IgAV, because of the self-limited nature of the disease, specific treatment is not required. For IgAVN there are two recommendations that can be used in treatment. The Kidney Disease Improving Global Outcomes (KDIGO) practice guideline on glomerulonephritis provides recommendations for the

treatment of IgAVN in children and adults. The second and the newer ones are European consensus-based recommendations for diagnosis and treatment of IgA vasculitis developed by the SHARE initiative (but they are recommended according to the clinical course without results of kidney biopsy) [5].

We are searching for markers that would predict the progress of nephropathy in the course of IgAV or the severity of IgAVN.

The aim of the study is to present the currently known biomarkers in IgAV and IgAVN.

Pathogenesis

The exact pathogenesis is unknown [21]. It is currently considered that genetic, inflammatory, environmental, and some other factors are significant [22]. According to the latest multi-hit hypothesis [2] four processes are fundamental to the outset and progression of IgAVN: 1) overproduction of galactose-deficient IgA1 (Gd-IgA1) and 2) antibodies directed against galactose-deficient IgA1 (anti-Gd-IgA1), 3) formation of pathogenic immune complexes, 4) accumulation of these complexes in the glomeruli [2, 23, 24]. The presence of Gd-IgA1 complexes alone is not pathognomonic for IgAVN. They were confirmed in lupus nephritis, membranous nephropathy, and Sjogren’s syndrome [24]. Furthermore, elevated levels of serum Gd-IgA1 were present among healthy relatives of patients with IgAVN [25]. Therefore, it is considered that its presence in serum does not result in nephropathy development but glomeruli are damaged due to the production of anti-Gd-IgA1 antibodies [26]. Gd-IgA1 components build im-

immune complexes connecting with each other, with IgG antibodies, or other molecules including the Fc fragment of IgA receptor (Fc α RI/CD89), and soluble transferrin receptor (sTfR/CD71), increased expression of which is confirmed in IgAVN [2, 11]. Immune complexes consisting of Gd-IgA1 with IgG antibodies are macromolecules and accumulate in the glomerular mesangium, which, through activation of the complement system, leads to inflammation, fibrosis, and ultimately impaired renal function [23, 25]. Complement system activation (*via* the lectin or alternative pathway) plays a key role in the exacerbation of renal impairment [24–29]. According to the latest findings about IgAVN pathogenesis, abnormality in the function of two receptors in disease development is crucial: Fc α RI (CD89) on leucocytes and sTfR (CD71) on mesangial cells of glomeruli [30, 31]. Based on current data, Fc α RI/CD89, the specific IgA receptor in the serum of patients with IgAVN, is relevant in the etiology of IgA vasculitis due to the induction of migration of neutrophils and their activation [2]. IgAVN is the inflammatory disease, but the exact role of immune cells is not completely understood. Anti-endothelial cell antibodies (AECA) are significant in this process are released in response to some genetic and/or environmental factors. They cause vascular damage through antibody-dependent cellular cytotoxicity and activation of endothelial cells. At the site of inflammation, mediators are activated, with the release of cytokines and chemokines, e.g. tumor necrosis factor α (TNF- α), interleukin (IL)-6, IL-8, a proliferation-inducing ligand (APRIL), and monocyte chemoattractant protein-1 (MCP-1) [28, 32]. The relation between respiratory tract infection and the onset or progression of the disease was confirmed in the scientific literature [33]. Receptor expression is substantial, especially toll-like receptors (TLR), located in mucous membrane tissues, and immune and kidney cells [24]. TLR4 overproduction is associated with nephropathy progression in IgAV. Because impaired glycosylation and galactosylation of IgA and altered gene expression of proteins involved in glycosylation, e.g. β -1,3-galactosyltransferase, core 1 synthase glycoprotein-N-acetylgalactosamine 3- β -galactosyltransferase (C1GALT1) and C1GALT1 specific chaperone 1 (C1GALT1C1), are relevant in disease pathogenesis, they might also influence the disease progression [25].

Genetics

Genetic factors are likely to be crucial in IgAVN pathogenesis. There are some reports of hereditary prevalence or geographical differences in disease occurrence. Also, genetic association studies suggest a contribution of common variants [29]. He *et al.* in their meta-analysis about IgAV described many different genetic factors predisposing to a severe course of the disease or having a protective effect [34]. Among genes having mutations as-

sociated with IgAVN and poor prognosis, angiotensin-converting enzyme (ACE), IL-8, and HLA-B*35 genes were detected although reports from different authors are inconsistent, suggesting the need for further research [34, 35]. The authors highlighted that this disease is not related to a single gene mutation but occurs due to a combination of individual risk factors, which together with environmental factors contribute to the onset of the disease and determine its severity. So far, however, more comprehensive genome-wide association studies (GWAS) have not been published. Two pediatric population studies on IgAN and IgAV with/without nephritis – Genomics of IgA-related disorders in kids, USA (GIGA-kids) and GIGA-Europe Study – are in progress [29].

Biomarkers

Many molecules are involved in the pathogenesis of IgAVN, e.g. biomarkers, which among well-known factors such as proteinuria, arterial hypertension, or lower GFR, have a prognostic role [3, 11, 36].

Biomarkers, by definition, are objectively measurable biological indicators, which suggest the presence of the disease and enable the assessment of its course including its response to treatment [37].

Besides well-known factors such as proteinuria or lower glomerular filtration rate (GFR), the need for the identification of early disease biomarkers was also pointed out [36].

Over the past few years, they have become the subject of many studies on IgAVN, although the obtained results are equivocal and require further investigation, especially among pediatric patients [11].

Gd-IgA1

One of the best known IgAVN biomarkers is Gd-IgA1, i.e. IgA1 with galactose-deficient, O-linked, hinge-region glycans and free N-acetyl galactosamine residue. This is caused by an abnormality of the glycosylating process due to e.g. low expression of GALNT2 (polypeptide N-acetylgalactosaminyltransferase 2), C1GALT1 (core 1 synthase, glycoprotein-N-acetylgalactosamine 3- β -galactosyltransferase 1) and COSMC (core 1 β -Gal-T-specific molecular chaperone). Gd-IgA1, due to free N-acetyl galactosamine residues, tends to build polymeric structures and stimulate antibody production [38]. Pathogenesis of the abnormal glycosylation of IgA1 is still unknown; however, some suggest exposure to infectious factors (viral or bacterial) and diet in addition to environmental and genetic components.

Many authors have proved the statistically significant higher concentration of this molecule in the serum of patients with IgAVN in comparison to patients with IgAV without nephropathy. A higher concentration of Gd-IgA1 is a risk factor for disease progression and development of kidney failure [11, 23, 24, 29, 36, 39–41]. Suzuki *et al.*

confirmed a higher concentration of Gd-IgA1 among patients with the active form of IgAVN rather than in remission [40]. Gd-IgA1 level might be hereditary since some studies demonstrated its higher concentration levels among healthy relatives of the patients with IgAVN, and galactosylation of IgA1 is partially determined by single nucleotide polymorphism of C1GALT1 [25].

Anti-Gd-IgA1 antibodies

Auto-antibodies, including IgA and IgG class (anti-Gd-IgA1), higher concentrations of which were confirmed among patients with IgAVN rather than with IgAV, are produced as a response against galactose-deficient IgA1 circulating in serum [29, 38]. Furthermore, cross-reactive anti-endothelial cell antibodies (AECA) may emerge as the result of infection with pathogens, which have antigen structures similar to walls of human blood vessels, or under the influence of genetic factors.

Immunoglobulin G (IgG) is of great importance in the progression of IgAV nephropathy. Both Gd-IgA1 level and specific anti-Gd-IgA1 immunoglobulin G may be useful in monitoring the severity of IgAV nephropathy [29, 40].

Gd-IgA1-anti-Gd-IgA1 immune complexes

Circulation and aggregation of immune complexes in serum results in their accumulation in the endothelium of small blood vessels, e.g. in skin, synovial membrane, intestine, and kidneys. Moreover, immune complexes as a result of combining Gd-IgA1 and anti-Gd-IgA1 can activate the component system. They may also stimulate the proliferation of mesangial cells in glomeruli and induce cell proliferation through accumulation in the mesangium. Furthermore, they can release inflammatory mediators and cause kidney failure. Gd-IgA1-anti-Gd-IgA1 immune complexes were detected in the serum of all patients with IgAV independently of renal involvement. Serum levels of these immune complexes are higher among patients with IgAVN in comparison to patients with IgAV without renal involvement [11, 38, 42, 43]. Additionally, sera of patients with IgAV immune complexes do not contain IgG, whereas IgG immune complexes were found in IgAVN patients [2, 43, 44]. Moreover, the concentration of circulating immune complexes correlates with the severity of the disease and its progression [2, 10]. In the study by Pillebout *et al.* levels of these complexes were only associated with nephritis [11].

The latest identified biomarkers of IgAVN among the adult population include Fc fragment of IgA receptor (Fc α RI/CD89) and soluble transferrin receptor (sTfR/CD71).

Fc α RI/CD89 is the Fc fragment of the IgA receptor and is present on the surface of phagocytes produced in the bone marrow: neutrophils, eosinophils, and monocytes/macrophages. Fc α RI may exist as a trans-membrane receptor on myeloid cells and as a soluble form in the blood (sCD89) [30, 45]. According to Moresco *et al.*,

urine sCD89 might be a potential biomarker used to assess IgAVN activity – its levels are decreased among patients with active forms of the disease [46]. Furthermore, the soluble form of the receptor can establish immune complexes with Gd-IgA1 and immunoglobulin G. Complexes are nephrotoxic due to their huge dimensions – they accumulate in glomeruli. Higher levels of them were confirmed in urine samples of patients with IgAVN [10, 11, 25]. The concentration of serum Gd-IgA1-sCD89 complexes is associated with the severity of IgAVN and its progression.

The second significant receptor in the pathogenesis of IgAVN is the soluble transferrin receptor (sTfR/CD71), which might be helpful in the diagnosis and prognosis of IgAVN [41, 47-49]. Serum sTfR of healthy individuals does not penetrate the glomerular membrane. Nevertheless, it may infiltrate into the urine in the case of proteinuria due to damage of the glomerular basement membrane. The study by Delanghe *et al.* among adult individuals showed that concentration of urinary sTfR correlates with disease severity, i.e. it progresses with proteinuria. Furthermore, a reduction in the amount of the receptor in the urine was observed as a consequence of glucocorticosteroid therapy. It may suggest that the receptor may have various functions – detection of nephropathy in the course of IgAV, monitoring of its progression, or assessment of treatment effectiveness [47]. An and Xia's study among pediatric patients also confirmed the association of higher TfR levels with an increase in proteinuria [41]. Zhang *et al.*'s *in vitro* study proved the impact of Gd-IgA1 on increased expression of soluble transferrin receptor (TfR/CD71), which induces proliferation of mesangial cells [50].

IL-6 and IL-8

Overproduction of the components of protoplasm and chemokines release, e.g. IL-6 and IL-8, is the result of excessive proliferation of mesangial cells.

Interleukin 6 through T-cells' activation stimulates mesangial proliferation and fibrosis. IL-8, whose production is stimulated by e.g. IgA1-AECA in walls of small vessels, causes neutrophil chemotaxis, and thus to destruction of vascular endothelial cells [10, 22, 51, 52].

Kimura *et al.*'s research results demonstrated that serum IL-8 levels among adult patients with IgAVN were significantly higher than in IgAV [53]. However, research by Pillebout *et al.* and Yuan *et al.* in children showed elevated serum IL-8 levels in all patients with IgAV regardless of the presence of nephropathy [11, 51], although Yuan *et al.* detected that its serum levels related to severity of proteinuria in IgAVN [51]. IL-8 urine level among children and adults was significantly higher in a group of patients with IgAVN in comparison to IgAV, which suggests its potential role as a marker of nephropathy progression [11, 36, 51, 52].

Due to its elevated urine concentrations in this group of patients, IL-8 in urine may also be a marker of IgAVN [11, 36].

KIM-1, MCP1, NAG, UAGT and NGAL

The most recent meta-analysis of urine biomarkers in children with IgAV highlights the importance of kidney injury molecule (KIM-1), monocyte chemotactic protein-1 (MCP-1), N-acetyl-β-glucosaminidase (NAG), angiotensinogen (UAGT) and neutrophil gelatinase-associated lipocalin (NGAL) as the most promising molecules in predicting the development of nephritis before the appearance of clinical symptoms [11, 36, 48]. Several studies on the significance of these markers in children with IgAVN have been published in the past few years [32, 54-58]. Marro *et al.* in their recent study evaluated 124 various urine molecules in children with IgAV, which may be relevant in IgAV/N pathology [54]. Urine UAGT, KIM-1 and MCP-1 levels in children with IgAVN were, among others, statistically significantly higher in comparison to IgAV [54]. These conclusions confirmed the results of other studies, as demonstrated in the meta-analysis by Williams *et al.* [25, 48], in studies on concentrations of urine MCP-1

[58, 59], and in Yi-fei *et al.*'s investigation, where higher levels of UAGT in the urine of patients with IgAVN were detected [57]. The results of Dyga *et al.*, in contrast, did not confirm a significant difference between KIM-1 levels in the urine of patients with IgAVN and IgAV [55]. These results need further research.

Vanin-1 is the modern marker of oxidative stress, whose levels are elevated in acute kidney injury (AKI), and might also be a biomarker of the active inflammatory process in children with IgAVN; however, it should be confirmed in a larger group of individuals [60].

Metabolomics

To improve understanding of disease pathogenesis and search for factors modifying its course, some researchers investigate metabolomics, i.e. analysis of metabolism. Demir *et al.* used metabolic profiling and detected elevated DHAP (18:0), prostaglandin D2/I2, porphobilinogen,

Table 2. Analyzed biomarkers in urine and serum

Biomarker		References
Serum		
GdIgA1	IgAVN > IgAV	[11, 23, 24, 29, 36, 39-41]
Anti-Gd-IgA1 (IgG)	IgAVN > IgAV, related to activity of disease in patients with IgAVN	[30, 38, 40]
Immune complexes containing GdIgA1	High level of IgG-GdIgA1 (large molecules) only in IgAVN	[2, 42]
	Non-IgG complexes (small molecules) IgAVN > IgAV	[38, 43]
NGAL	Present in IgAVN and IgAV, unrelated to proteinuria and GFR	[11, 36]
IL-8	IgAVN > IgAV	[53]
	IgAV > healthy control	[11, 51]
	In IgAVN related to severity of proteinuria	[51]
Urine		
GdIgA1	IgAVN > IgAV	[11, 36, 44]
GdIgA1-IgG	IgAVN > IgAV	[11, 29]
sCD89	Active IgAVN < non-active IgAVN	[40]
GdIgA1-sCD89	IgAVN > IgAV	[10, 11, 25]
IL-6	IgAVN > IgAV	[11, 36]
IL-8	IgAVN > IgAV	[11, 36, 51, 52]
sTfR	IgAVN > IgAV	[41, 48]
NGAL	Present in IgAV and IgAVN, unrelated to proteinuria and GFR	[11, 36]
	IgAVN > IgAV	[29, 36]
IgA-sCD89	Elevated only in IgAVN	[11, 36]
IgA-IgG	Elevated only in IgAVN	[11, 36]
MCP-1	IgAVN > IgAV	[48, 59]
Vanin-1	Active IgAVN	[60]

Gd-IgA1 – galactose-deficient IgA1, *anti-Gd-IgA1 (IgG)* – antibodies directed against galactose-deficient IgA1 (class IgG), *NGAL* – neutrophil gelatinase-associated lipocalin, *GdIgA1-IgG* – complexes consisted of GdIgA1 and IgG, *sCD89* – soluble Fc fragment of IgA receptor, *GdIgA1-sCD89* – complexes consisting of GdIgA1 and sCD89, *IL-6* – interleukin 6, *IL-8* – interleukin 8, *sTfR* – soluble transferrin receptor, *IgA-sCD89* – complexes consisting of IgA and sCD89, *IgA-IgG* – complexes consisting of IgA and IgG, *MCP-1* – monocyte chemoattractant protein 1




Fig. 1. Pathogenesis and some biomarkers in immunoglobulin A (IgA) vasculitis (IgAV) and IgA vasculitis with nephritis (IgAVN)

C1GALT1 – core 1 synthase glycoprotein-N-acetylgalactosamine 3-β-galactosyltransferase, *C1GALTC2* – *C1GALT1* specific chaperone 1, *Gd-IgA1* – galactose-deficient IgA1, anti-*Gd-IgA1* (IgG) – antibodies directed against galactose-deficient IgA1 (class IgG), *TNF-α* – tumor necrosis factor α, *IL-6* – interleukin 6, *IL-8* – interleukin 8, *APRIL* – a proliferation-inducing ligand, *AECA* – anti-endothelial cell antibodies, *MCP1* – monocyte chemoattractant protein 1, *sCD89* – soluble Fc fragment of IgA receptor, *GdIgA1-sCD89* – complexes consisted of *GdIgA1* and *sCD89*, *sTfR* – soluble transferrin receptor, *NGAL* – neutrophil gelatinase-associated lipocalin, *IgA-sCD89* – complexes consisted of *IgA* and *sCD89*, *GdIgA1-IgG* – complexes consisting of *GdIgA1* and *IgG*, *IgA-IgG* – complexes consisting of *IgA* and *IgG*

5-methyltetrahydrofolic acid, and N-acetyl-4-O-acetylneuraminic acid/N-acetyl-7-O-acetylneuraminic acid concentrations in patients with IgAVN before nephropathy development in contrast to a group with IgAV but without nephropathy [3]. Sun *et al.* and their metabolomic analysis provided information that (S)-3-hydroxyisobutyric acid, p-cresol sulfate, and 3-carboxy-4-methyl-5-pentyl-2-furanpropanoic acid are related to progression from IgAV to IgAVN [61]. Moreover, previous studies [3, 62] indicate

the influence of platelet-activating factor (PAF), prostaglandins, and arachidonic acid on nephropathy progression.

Summarizing the present evidence, many potential biomarkers for the prediction of nephropathy development in the course of IgAV are currently under investigation (Table 2, Fig. 1). Further studies are important to early planning of treatment and monitoring of its effectiveness, or assessment of disease progression. Nevertheless an increased serum level of Gd-IgA1 is still the most consistent finding

in patients with IgAV. For the diagnosis of IgAV with nephritis and to predict prognosis, urinary biomarkers seem to have an advantage over serum biomarkers, because they are more specific to the kidneys. In predicting the development of nephritis in patients with IgAV nephritis before the appearance of clinical symptoms very promising new biomarkers are KIM-1, MCP-1, NAG and UAGT.

Funding

This research received no external funding.

Disclosures

Approval of the Bioethics Committee was not required. The authors declare no conflict of interest.

References

- Piram M, Mahr A (2013): Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. *Curr Opin Rheumatol* 25: 171-178.
- Heineke MH, Ballering AV, Jamin A, et al. (2017): New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). *Autoimmun Rev* 16: 1246-1253.
- Demir S, Kaplan O, Celebier M, et al. (2020): Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis. *Semin Arthritis Rheum* 50: 1238-1244.
- Ozen S, Pistorio A, Iusan SM, et al. (2010): EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. *Ann Rheum Dis* 69: 798-806.
- Mizerska-Wasiak M, Kuszal M. Zapalenie naczyń związane z IgA. In: Zapalenia naczyń w praktyce klinicznej interdyscyplinarnie. Kołacz A, Kossarzecka E (Eds.). PZWL Wydawnictwo Lekarskie, Warszawa 2022; 416-418.
- Sestan M, Jelusic M (2023): Diagnostic and management strategies of IgA vasculitis nephritis/Henoch-Schönlein purpura nephritis in pediatric patients: Current perspectives. *Pediatric Health Med Ther* 14: 89-98.
- Komatsu H, Fujimoto S, Yoshikawa N, et al. (2016): Clinical manifestations of Henoch-Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). *Clin Exp Nephrol* 20: 552-560.
- Delbet JD, Parmentier C, Rea CH, et al. (2021): Management of IgA vasculitis with nephritis. *Pediatric Drugs* 23: 425-435.
- Pohl M (2015): Henoch-Schönlein purpura nephritis. *Pediatr Nephrol* 30: 245-252.
- Dyga K, Szczepańska M (2020): IgA vasculitis with nephritis in children. *Adv Clin Exp Med* 29: 513-519.
- Pillebout E, Jamin A, Ayari H, et al. (2017): Biomarkers of IgA vasculitis nephritis in children. *PLoS One* 12: e0188718.
- Shi D, Chan H, Yang X, et al. (2019): Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis. *PLoS One* 14: e0223218.
- Mizerska-Wasiak M, Turczyn A, Cichoń-Kawa K, et al. (2021): IgA vasculitis nephritis clinical course and kidney biopsy – national study in children. *Pediatric Rheumatology* 19: 150.
- Edstrom-Halling S, Soderberg MP, Berg UB (2010): Predictors of outcome in Henoch-Schönlein nephritis. *Pediatr Nephrol* 25: 1101-1108.
- Kawasaki Y, Suzuki J, Sakai N, et al. (2003): Clinical and pathological features of children with Henoch-Schönlein nephritis: risk factors associated with poor prognosis. *Clin Nephrol* 60: L153-160.
- Mir S, Yavascan O, Mutlubas F, et al. (2007): Clinical outcome in children with Henoch-Schönlein nephritis. *Pediatr Nephrol* 22: 64-70.
- Chan H, Tang YL, Lv XH, et al. (2016): Risk factors associated with renal involvement in childhood Henoch-Schönlein purpura: a meta-analysis. *PLoS One* 11: e0167346.
- Jelusic M, Sestan M, Cimaz R, et al. (2019): Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? *Pediatr Rheumatol* 17: 10.
- Trimarchi H, Barratt J, Cattran DC, et al. (2017): IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Conference Participants. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. *Kidney Int* 91: 1014-1021.
- Jelusic M, Sestan M, Giani T, Cimaz R (2022): New insights and challenges associated with IgA vasculitis and IgA vasculitis with nephritis – is it time to change the paradigm of the most common systemic vasculitis in childhood? *Front Pediatr* 10: 853724.
- Pan YX, Ye Q, Shao WX, et al. (2014): Relationship between immune parameters and organ involvement in children with Henoch-Schönlein purpura. *PLoS One* 9: e115261.
- Chen XQ, Tu L, Tang Q, et al. (2022): An emerging role for neutrophil extracellular traps in IgA vasculitis: A mini-review. *Front Immunol* 13: 912929.
- Suzuki H, Yasutake J, Makita Y, et al. (2018): IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. *Kidney Int* 93: 700-705.
- Nusken E, Weber LT (2022): IgA vasculitis nephritis. *Curr Opin Pediatr* 34: 209-216.
- Peruzzi L, Coppo R (2021): IgA vasculitis nephritis in children and adults: one or different entities? *Pediatr Nephrol* 36: 2615-2625.
- Suzuki H, Kiryluk K, Novak J (2011): The pathophysiology of IgA nephropathy. *J Am Soc Nephrol* 22: 1795-1803.
- Chua JS, Zandbergen M, Wolterbeek R, et al. (2019): Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. *Mod Pathol* 32: 1147-1157.
- Imai T, Nishiyama K, Ueki K, et al. (2020): Involvement of activated cytotoxic T lymphocytes and natural killer cells in Henoch-Schönlein purpura nephritis. *Clin Transl Immunology* 9: e1212.
- Hastings MC, Rizk DV, Kiryluk K, et al. (2022): IgA vasculitis with nephritis: update of pathogenesis with clinical implications. *Pediatr Nephrol* 37: 719-733.
- Morton HC, Brandtzaeg P (2001): CD89: the human myeloid IgA Fc receptor. *Arch Immunol Ther Exp* 49: 217-229.
- Haddad E, Moura IC, Arcos-Fajardo M, et al. (2003): Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. *J Am Soc Nephrol* 14: 327-337.
- Wang J, Ying Q, Zhong S, et al. (2018): Elevated urinary monocyte chemoattractant protein-1 levels in children with

- Henoch-Schonlein purpura nephritis. *Pediatr Neonatol* 59: 238-243.
33. Davin JC, Coppo R (2014): Henoch-Schonlein purpura nephritis in children. *Nat Rev Nephrol* 10: 563.
 34. He X, Yu C, Zhao P, et al. (2013): The genetics of Henoch-Schonlein purpura: a systematic review and meta-analysis. *Rheumatol Int* 33: 1387-1395.
 35. Oni L, Sampath S (2019): Childhood IgA vasculitis (Henoch-Schonlein purpura) – advances and knowledge gaps. *Fron Pediatr* 7: 257.
 36. Berthelot L, Jamin A, Viglietti D, et al. (2018): Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. *Nephrol Dial Transplant* 33: 1579-1590.
 37. Larson H, Chan E, Sudarsanam S, Johnson DE (2013): Biomarkers. *Methods Mol Biol* 930: 253-273.
 38. Mizerska-Wasiak M, Gajewski Ł, Cichoń-Kawa K, et al. (2018): Serum GDIG1 levels in children with IgA nephropathy and Henoch-Schönlein nephritis. *Cent Eur J Immunol* 43: 162-167.
 39. Zhang X, Xie X, Shi S, et al. (2020): Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. *Nephrol Dial Transplant* 35: 2117-2123.
 40. Suzuki H, Moldoveanu Z, Julian BA, et al. (2019): Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. *Kidney Int Rep* 4: 1717-1724.
 41. An JK, Xia D (2018): Diagnostic performance of urinary proteins as biomarkers in evaluating Henoch Schonlein purpura nephritis. *Clin Exp Med* 11: 12354-12360.
 42. Mayer-Hain S, Gebhardt K, Neufeld M, et al. (2022): Systemic activation of neutrophils by immune complexes is critical to IgA vasculitis. *J Immunol* 209: 1048-1058.
 43. Coppo R, Basolo B, Martina G, et al. (1982): Circulating Immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity. *Clin Nephrol* 18: 230-239.
 44. Davin JC, Ten Berge IJ, Weening JJ (2001): What the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? *Kidney Int* 59: 823-834.
 45. Monteiro RC, Kubagawa H, Cooper MD (1990): Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. *J Exp Med* 171: 597-613.
 46. Moresco RN, Speeckaert MM, Zmonarski SC, et al. (2016): Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and Henoch-Schönlein purpura nephritis. *BBA Clin* 5: 79-84.
 47. Delanghe SE, Speeckaert MM, Segers H, et al. (2013): Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schönlein purpura nephritis. *Clin Biochem* 46: 591-597.
 48. Williams CEC, Toner A, Wright RD, Oni L (2021): A systematic review of urine biomarkers in children with IgA vasculitis nephritis. *Pediatr Nephrol* 36: 3033-3044.
 49. Zhang R, Sung SHP, Feng G, et al. (2018): Aggregation-induced emission probe for specific turn-on quantification of soluble transferrin receptor: An important disease marker for iron deficiency anemia and kidney diseases. *Anal Chem* 90: 1154-1160.
 50. Zhang Q, Yan L, Chen M, et al. (2019): IgA1 isolated from Henoch-Schönlein purpura children promotes proliferation of human mesangial cells in vitro. *Cell Biol Int* 43: 760-769.
 51. Yuan L, Wang Q, Zhang S, Zhang L (2018): Correlation between serum inflammatory factors TNF- α , IL-8, IL-10 and Henoch-Schonlein purpura with renal function impairment. *Exp Ther Med* 15: 3924-3928.
 52. Lin CY, Yang YH, Lee CC, et al. (2006): Thrombopoietin and interleukin-6 levels in Henoch-Schonlein purpura. *J Microbiol Immunol* 39: 476-482.
 53. Kimura S, Takeuchi S, Soma Y, Kawakami T (2013): Raised serum levels of interleukins 6 and 8 and antiphospholipid antibodies in an adult patient with Henoch-Schönlein purpura. *Clin Exp Dermatol* 38: 730-736.
 54. Marro J, Chetwynd AJ, Wright RD, et al. (2022): Urinary protein array analysis to identify key inflammatory markers in children with IgA vasculitis nephritis. *Children* 9: 622.
 55. Dyga K, Machura E, Swietochowska E, Szczepańska M (2020): Analysis of the association between kidney injury biomarkers concentration and nephritis in immunoglobulin A vasculitis: A pediatric cohort study. *Int J Rheum Dis* 23: 1184-1193.
 56. Mao YN, Liu WEI, Li YG, et al. (2012): Urinary angiotensinogen levels in relation to renal involvement of Henoch-Schonlein purpura in children. *Nephrology* 17: 53-57.
 57. Yi-fei M, Yu-feng L, Gui-mei G, et al. (2020): Changes of new urinary biomarkers in children with Henoch-Schonlein purpura nephritis. *J Shanghai Jiaotong Univ Med Sci* 40: 841.
 58. Shuai Z, Huijun S, Weizhong G, et al. (2017): Evaluation of TGF- β 1 and MCP-1 expression and tubulointerstitial fibrosis in children with Henoch-Schonlein purpura nephritis and IgA nephropathy: A clinical correlation. *Clinics* 72: 95-102.
 59. Fuentes Y, Hernandez AM, Garci-Roca P, et al. (2014): Urinary MCP-1/creatinine in Henoch-Schonlein purpura and its relationship with nephritis. *Pediatr Nephrol* 29: 1047-1052.
 60. Mizerska-Wasiak M, Platos E, Cichoń-Kawa K, et al. (2022): The usefulness of vanin-1 and periostin as markers of an active autoimmune process or renal fibrosis in children with IgA nephropathy and IgA vasculitis with nephritis – a pilot study. *J Clin Med* 11: 1265.
 61. Sun L, Xie B, Zhang Q, et al. (2017): Biomarkers identification by a combined clinical and metabolomics analysis in Henoch-Schonlein purpura nephritis children. *Oncotarget* 8: 114239-114250.
 62. Coppo R, Fonsato V, Balegno S, et al. (2010): Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. *Kidney Int* 77: 417-427.